Daratumumab - Janssen Biotech
Alternative Names: Anti-CD38-monoclonal-antibody-Genmab; DALINVI; Dara-IV; Darasarex; daratumumab and hyaluronidase-fihj; DARZALEX; DARZALEX SC; Humanised anti-CD38 monoclonal antibody; HuMax-CD38; HuMax®-CD38 - Genmab; JNJ-54767414Latest Information Update: 13 Mar 2024
At a glance
- Originator Genmab
- Developer Amgen; Boston Medical Center; Bristol-Myers Squibb; Dana-Farber Cancer Institute; French Innovative Leukemia Organisation; Genentech; Genmab; Janssen Biotech; Janssen Research & Development; Janssen-Cilag; Johnson & Johnson Innovative Medicine; M. D. Anderson Cancer Center; Onyx Pharmaceuticals; Syros Pharmaceuticals; Weill Cornell Medical College
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Apoptosis stimulants; Phagocyte stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Multiple myeloma
- Registered Amyloid light-chain amyloidosis
- Phase III Plasmablastic lymphoma
- Phase II Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Myelodysplastic syndromes; Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma; T-cell lymphoma; Waldenstrom's macroglobulinaemia
- Phase I/II Solid tumours
- Phase I Prostate cancer
- Suspended Non-small cell lung cancer
Most Recent Events
- 06 Mar 2024 Preregistration for Multiple myeloma (Combination therapy, Newly diagnosed) in European Union (SC)
- 06 Mar 2024 Efficacy and adverse events data from phase III Perseus trial in Multiple myeloma released by Johnson & Johnson
- 31 Jan 2024 Daratumumab is still in phase I trials for Prostate cancer in USA (NCT03177460)